Tardive dyskinesia and glucid metabolism

Brousse, Georges; Méary, Alexandre; Mouret, J; Blanc, Olivier; Hueber, Thierry; Lemoine, Philippe; Llorca, Pierre‐Michel; Lachaux, B.

doi:10.1002/hup.860

Cited by 3 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…l'hyponatré-mie et la polydipsie attribuables à plusieurs mécanismes pathophysiologiques [4]. Une interaction complexe entre une v ariation importante des taux de glucose dans le système nerveux central et une hypersensibilité des récep-teurs d opaminergiques serait responsable de l'apparition des d yskinésies tardives [14]. Le psychiatre a le devoir d'être a ttentif à ces aspects et, le cas échéant, de collaborer avec le médecin traitant ou le gériatre dans la prise en soin du p atient.…”

Section: Traitements Biologiquesunclassified

Prise en soins de la schizophrénie chez la personne âgée

2011

Swiss Arch Neurol Psychiatr

View full text Add to dashboard Cite

SummaryCare of the elderly schizophrenic patient Despite the development of new aetiopathological models the treatment of late-life schizophrenia is still based essentially on antipsychotic medication. The absence of research specifically targeting late-life schizophrenics limits the value of recommendations on indication, dosage and treatment alternatives, particularly as the latter have scant regard for the age of schizophrenia onset (early, late, very late onset), for the various comorbidities and the polymedication so common in the elderly. The use of atypical neuroleptics at adapted doses should be combined with biopsychosocial care and treatment of psychiatric and somatic comorbidities. The choice of an adapted treatment is often conditioned, especially if early schizophrenia is con sidered, by many years of treatment and side effects which may limit compliance when the evolution itself has been unfavourable with persistent, sometimes handi capping residual symptoms. Moreover, schizophrenia is complicated by c ognitive disorders for which the best therapeutic approach in the elderly remains uncertain.

show abstract

Section: Traitements Biologiquesunclassified

Prise en soins de la schizophrénie chez la personne âgée

2011

Swiss Arch Neurol Psychiatr

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract